WO2019013583A3 - 약제학적 제제 및 그 제조방법 - Google Patents

약제학적 제제 및 그 제조방법 Download PDF

Info

Publication number
WO2019013583A3
WO2019013583A3 PCT/KR2018/007950 KR2018007950W WO2019013583A3 WO 2019013583 A3 WO2019013583 A3 WO 2019013583A3 KR 2018007950 W KR2018007950 W KR 2018007950W WO 2019013583 A3 WO2019013583 A3 WO 2019013583A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
release
active ingredient
mirabegron
controlling
Prior art date
Application number
PCT/KR2018/007950
Other languages
English (en)
French (fr)
Other versions
WO2019013583A2 (ko
Inventor
윤재희
강한
Original Assignee
주식회사 대웅제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180007928A external-priority patent/KR101937713B1/ko
Application filed by 주식회사 대웅제약 filed Critical 주식회사 대웅제약
Priority to CN201880044152.8A priority Critical patent/CN110869008B/zh
Priority to EP18832644.1A priority patent/EP3653202B1/en
Priority to US16/626,084 priority patent/US11433054B2/en
Priority to JP2020520420A priority patent/JP6870177B2/ja
Publication of WO2019013583A2 publication Critical patent/WO2019013583A2/ko
Publication of WO2019013583A3 publication Critical patent/WO2019013583A3/ko
Priority to PH12020550009A priority patent/PH12020550009A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명의 약제학적 제제는 활성성분과 활성성분의 방출을 조절하는 방출제어제를 포함하고, 활성성분은 미라베그론 및 그의 약학적으로 허용가능한 염 중에서 선택된 적어도 하나이고, 방출제어제는 하이드로겔 형성 고분자이며, 하이드로겔 형성 고분자는 폴리에틸렌옥시드, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스나트륨, 및 히드록시에틸셀룰로오스 중에서 선택된 적어도 하나이고, 평균 분자량은 10만 내지 800만이다. 본 발명은, 제제 중 불순물 생성은 억제하고, 미라베그론 및 그의 약학적으로 허용가능한 염 중에서 선택된 적어도 하나의 방출을 효과적으로 제어할 수 있다는 장점을 갖는다.
PCT/KR2018/007950 2017-07-14 2018-07-13 약제학적 제제 및 그 제조방법 WO2019013583A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201880044152.8A CN110869008B (zh) 2017-07-14 2018-07-13 药物制剂及其制备方法
EP18832644.1A EP3653202B1 (en) 2017-07-14 2018-07-13 Pharmaceutical preparation and preparation method therefor
US16/626,084 US11433054B2 (en) 2017-07-14 2018-07-13 Pharmaceutical preparation and preparation method therefor
JP2020520420A JP6870177B2 (ja) 2017-07-14 2018-07-13 薬剤学的製剤およびその製造方法
PH12020550009A PH12020550009A1 (en) 2017-07-14 2020-01-07 Pharmaceutical preparation and preparation method therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170089900 2017-07-14
KR10-2017-0089900 2017-07-14
KR10-2018-0007928 2018-01-22
KR1020180007928A KR101937713B1 (ko) 2017-07-14 2018-01-22 약제학적 제제 및 그 제조방법

Publications (2)

Publication Number Publication Date
WO2019013583A2 WO2019013583A2 (ko) 2019-01-17
WO2019013583A3 true WO2019013583A3 (ko) 2019-03-07

Family

ID=65002608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/007950 WO2019013583A2 (ko) 2017-07-14 2018-07-13 약제학적 제제 및 그 제조방법

Country Status (1)

Country Link
WO (1) WO2019013583A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113662922A (zh) * 2020-10-29 2021-11-19 北京莱瑞森医药科技有限公司 一种米拉贝隆缓释组合物及其制备方法和应用
WO2024128995A1 (en) * 2022-12-16 2024-06-20 Santa Farma Ilac Sanayii A.S. Pharmaceutical compositions of mirabegron

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050107298A (ko) * 2003-03-06 2005-11-11 아스텔라스세이야쿠 가부시키가이샤 방출 제어용 의약 조성물 및 이의 제조방법
KR20150045500A (ko) * 2012-08-31 2015-04-28 아스텔라스세이야쿠 가부시키가이샤 경구 투여용 의약 조성물
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
JP2016188181A (ja) * 2015-03-30 2016-11-04 アステラス製薬株式会社 ミラベグロン含有放出制御錠剤
JP2017048136A (ja) * 2015-09-01 2017-03-09 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346532B1 (en) 1997-10-17 2002-02-12 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
ZA200503510B (en) 2002-11-07 2006-12-27 Yamanouchi Pharma Co Ltd Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050107298A (ko) * 2003-03-06 2005-11-11 아스텔라스세이야쿠 가부시키가이샤 방출 제어용 의약 조성물 및 이의 제조방법
KR20150045500A (ko) * 2012-08-31 2015-04-28 아스텔라스세이야쿠 가부시키가이샤 경구 투여용 의약 조성물
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
JP2016188181A (ja) * 2015-03-30 2016-11-04 アステラス製薬株式会社 ミラベグロン含有放出制御錠剤
JP2017048136A (ja) * 2015-09-01 2017-03-09 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法

Also Published As

Publication number Publication date
WO2019013583A2 (ko) 2019-01-17

Similar Documents

Publication Publication Date Title
PH12020550009A1 (en) Pharmaceutical preparation and preparation method therefor
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
NZ710792A (en) Tofacitinib oral sustained release dosage forms
AU2018335259A1 (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
ECSP077987A (es) Formulación de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberación modificada
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
WO2017037593A3 (zh) 用于减少局部脂肪的医药组成物及其用途
MX2020014000A (es) Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
IN2012DN03377A (ko)
WO2019013583A3 (ko) 약제학적 제제 및 그 제조방법
FI3248597T3 (fi) Terapeuttinen aine sensorineuraaliseen kuulonmenetykseen
MX2023014946A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
JP2017523149A5 (ko)
MX342397B (es) Uso de fluido viscoelastico para producir un producto medicinal para tratar quirurgicamente el ojo.
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
MX2017015835A (es) Gel oftalmico de bimatoprost aplicable en gotas.
RU2015141792A (ru) Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя
WO2011080570A8 (en) Extended release pharmaceutical composition comprising linezolid and process for preparing the same
MX2021008248A (es) Composicion farmaceutica.
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
MY195591A (en) A Fast Disintegrating Pharmaceutical Composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18832644

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020520420

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018832644

Country of ref document: EP

Effective date: 20200214